685 Route 202/206 N
Suite 301
Bridgewater, NJ 08807
United States
800 775 7936
https://www.vynetherapeutics.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 10
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. David T. Domzalski | CEO, President & Director | 1,61M | N/D | 1967 |
Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer | 856,82k | N/D | 1973 |
Ms. Mutya Harsch J.D. | General Counsel, Chief Legal Officer & Company Secretary | 817,97k | N/D | 1975 |
Mr. Tyler Zeronda | CFO & Treasurer | N/D | N/D | 1987 |
Dr. Darrell S. Rigel FAAD, M.D. | Consultant | 40,2k | N/D | 1951 |
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
L'ISS Governance QualityScore di VYNE Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.